Rare and unknown diseases are a modern trend in medicine
https://doi.org/10.18705/2782-3806-2022-2-2-72-83
Abstract
Rare and unknown diseases are numerous and heterogeneous, characterized by low prevalence and relatively high mortality and disability rates. There are currently 6000–8000 rare diseases known to the scientific community, with an additional 250–280 new diseases being described each year. Both the difficulty of diagnosis and the lack of effective treatment for many of these diseases are pressing health problems throughout the world. The growing global interest in the problem of rare and unknown diseases and the search for its solution has led to the initiation of projects on rare, unknown and little-studied diseases in many countries.
About the Authors
E. S. Vasichkina
Ministry of Health of Russia
Russian Federation
Russian Federation
Elena S. Vasichkina, Head, Professor
Federal State Budgetary Institution "V. A. Almazov National Medical Research Center"
NCMU "Center for Personalized Medicine"
SIC of unknown, rare and genetically determined diseases
Institute of Medical Education
Faculty of Medicine
Department of Children's Diseases
197341
Akkuratova str., 2
Saint-Petersburg
A. A. Kostareva
Ministry of Health of Russia
Russian Federation
Russian Federation
Anna A. Kostareva, MD, Director, Associate Professor
Federal State Budgetary Institution "V. A. Almazov National Medical Research Center"
Institute of Molecular Biology and Genetics
Institute of Medical Education
Department of Internal Diseases
References
1. Valdez R., Ouyang L., Bolen J. Public health and rare diseases: oxymoron no more. Prev Chronic Dis. 2016; 13: E05.
2. European Organisation for Rare Diseases (EU-RORDIS). Rare diseases: understanding this public health priority. Eurordis, November 2005; 1–14.
3. Ferreira C. R. The burden of rare diseases. Am J Med Genet. 2019; 179A: 885–892.
4. Vaisitti T., Peritore D., Magistroni P., et al. The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. Orphanet J Rare Dis. 2021; 16: 374.
5. Angural A., Spolia A., Mahajan A., et al. Review: Understanding Rare Genetic Diseases in Low Resource Regions Like Jammu and Kashmir — India. Front Genet. 2020; 11: 415.
6. Costa T., Scriver C. R., Childs B., et al. The effect of Mendelian disease on human health: a measurement. Am. J. Med. Genet. 1985; 21: 231.
7. Valle D. L., Antonarakis S., Ballabio A., et al. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill; 2019. Accessed February 18, 2022.
8. Black N., Martineau F., Manacorda T. Diagnostic Odyssey for Rare Diseases: Exploration of Potential Indicators. Policy Innovation Research Unit. 2015; 1–65.
9. Glob. Comm. End Diagn. Odyssey Child. Rare Dis. 2019. Global Commission year one report. Rep., Glob. Comm. End Diagn. Odyssey Child. Rare Dis. https://globalrarediseasecommission.com/Report
10. Bick D., Jones M., Taylor S. L., et al. Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. J Med Genet. 2019 Dec; 56 (12): 783–791.
11. Huyard C. How did uncommon disorders become ‘rare diseases’? History of a boundary object. Soc Health Illn. 2009; 31: 463–77.
12. Van Weely S., Leufkens HGM. Priority Medicines for Europe and the World: a Public Health Approach to Innovation. WHO Background Paper 6.19. Rare Diseases. 2004. https://www.researchgate.net/publication/288946087_Priority_medicines_for_Europe_and_the_world_-_A_public_health_approach_to_innovation
13. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare OJ L 88. 2011; 45–65.
14. Undiagnosed rare diseases Content type: Review Orphanet Journal of Rare Diseases. 2021; 16: 446.
15. Procedural document on Epidemiology of rare disease in Orphanet, Orphanet, February 2019, Version 01.
16. Rare Diseases Act of 2002. United States Congress. 2002. https://history.nih.gov/research/down-loads/pl107-280.pdf. Accessed Jan 2020.
17. Makoto S., Kiyohito N. Development of orphan drugs in Japan: effects of a support system for development of orphan drugs in Japan. Drug Inf J. 2000; 34: 829–37.
18. Wakap S., Lambert D. M., et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database European Journal of Human Genetics. 2020; 28: 165–173.
19. Aymé and Rodwell. The European Union Committee of Experts on Rare Diseases: three productive years at the service of the rare disease communit. Orphanet Journal of Rare Diseases. 2014; 9: 30.
20. Kim S. Y., Lim B. C., Lee J. S., et al. The Korean undiagnosed diseases program: lessons from a one-year pilot project. Orphanet J Rare Dis. 2019; 14: 68.
21. Зинченко Р. А. Распространенность и вопросы диагностики редких (орфанных) заболеваний среди детского населения Российской Федерации / Р. А. Зинченко [и др.] Педиатрия им. Г. Н. Сперанского. – 2020. – 99 (4): 229–237.
22. Yang L., Su C., Lee A. M., et al. Focusing on rare diseases in China: are we there yet? Orphanet J Rare Dis. 2015 Nov; 10: 142.
23. Adachi T., Imanishi N., Ogawa Y., et al. Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from Japan’s initiative on rare and undiagnosed diseases (IRUD). Orphanet J Rare Dis. 2018; 13 (1): 208.
24. Takahashi I. Y., Mizusawa H. Initiative on Rare and Undiagnosed Disease in Japan. JMA J. 2021 Apr; 4 (2): 112–118.
25. Taruscio D., Baynam G., Cederroth H., et al. The Undiagnosed Diseases Network International: Five years and more! Mol Genet Metab. 2020; 129 (4): 243–254.
26. Macnamara E. F., D’Souza P. Undiagnosed Diseases Network, Tifft C. J. The undiagnosed diseases program: Approach to diagnosis. Transl Sci Rare Dis. 2019 Apr; 4 (3–4): 179–188.
27. Gainotti S., Mascalzoni D., Bros-Facer V., et al. Meeting Patients’ Right to the Correct Diagnosis: Ongoing International Initiatives on Undiagnosed Rare Diseases and Ethical and Social Issues. Int J Environ Res Public Health. 2018 Sep; 15 (10): 2072.
28. Schoch K., Esteves C., Bican A., et al. Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science. Genet Med. 2021 Feb; 23 (2): 259–271.
29. López-Martín E., Martínez-Delgado B., Bermejo-Sánchez E., et al. SpainUDP: The Spanish Undiagnosed Rare Diseases Program. Int J Environ Res Public Health. 2018 Aug; 15 (8): 1746.
30. Austin C. P., Cutillo C. M., Lau L. L., et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clinical and Transplantion Science. 2018; 11: 21–27.
31. Boycott K. M., Hartley T., Biesecker L. G., et al. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell. 2019; 177 (1): 32–37.
32. Taruscio D., et al. Undiagnosed Diseases Network International (UDNI): White paper for global actions to meet patient needs, Mol. Genet. Metab. 2015; 116 (4).
33. Hartley T., Lemire G., Kernohan K. D., et al. New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases. Annu Rev Genomics Hum Genet. 2020 Aug; 21: 351–372.
34. Burdick K. J., Cogan J. D., Rives L. C., et al. Undiagnosed Diseases Network. Limitations of exome sequencing in detecting rare and undiagnosed diseases. Am J Med Genet A. 2020 Jun; 182 (6): 1400–1406.
35. Splinter K., Adams D. R., et al. Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. N Engl J Med. 2018; 379: 2131–2139.
36. Harrison S. M., Riggs E. R., Maglott D.R, et al. Using ClinVar as a resource to support variant interpretation. Curr. Protoc. Hum. Genet. 2016; 89 (8): 1–23.
37. Salmon L. B., Orenstein N., Markus-Bustani K, et al. Improved diagnostics by exome sequencing following raw data reevaluation by clinical geneticists involved in the medical care of the individuals tested. Genet. Med. 2018; 21: 1443–51.
38. Murdock D. R., Rosenfeld J. A., Lee B. What Has the Undiagnosed Diseases Network Taught Us About the Clinical Applications of Genomic Testing? Annu Rev Med. 2022 Jan; 73: 575–585.
39. Baldridge D., Wangler M. F., Bowman A. N., et al. Model organisms contribute to diagnosis and discovery in the undiagnosed diseases network: current state and a future vision. Orphanet J Rare Dis. 2021; 16: 206.
40. Karczewski K. J., Francioli L. C., Tiao G., et al. Variation across 141, 456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. BioRxiv. 2019.
41. Studwell C. M., Kelley E. G. Family genetic result communication in rare and undiagnosed disease communities: Understanding the practice. J Genet Couns. 2021; 30 (2): 439–447.
42. Marshall D. A., Benchimol E. I., MacKenzie A., et al. Direct health-care costs for children diagnosed with genetic diseases are significantly higher than for children with other chronic diseases. Genet. Med. 2018. 21: 1049–5713.
43. Rare Diseases: Although Limited, Available Evidence Suggests Medical and Other Costs Can Be Substantial. GAO-22-104235. 2021.
44. Wohler E., Martin R., Griffith S., et al. PhenoDB, GeneMatcher and VariantMatcher, tools for analysis and sharing of sequence data. Orphanet J Rare Dis. 2021; 16: 365.
45. Bamshad M. J., Nickerson D. A., Chong J. X. Mendelian gene discovery: fast and furious with no end in sight. Am. J. Hum. Genet. 2019; 105: 448–55.
46. Groft S. C., Posada de la Paz M. Preparing for the Future of Rare Diseases. Adv Exp Med Biol. 2017; 1031: 641-648.
Review
For citations:
Vasichkina E.S., Kostareva A.A. Rare and unknown diseases are a modern trend in medicine. Russian Journal for Personalized Medicine. 2022;2(2):72-83. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-2-72-83
Views:
362
Email this article 